📌Variation in Renal Function Following Transition to #SacubitrilValsartan in 👥 w/ #HeartFailure
#CardioTwitter #CardioEd #PARADIGMHF #PARAGONHF
With ⬆️ data distinguishing HFmrEF from HFrEF and HFpEF, and new release of #PARAGONHF with subgroup analysis showing benefit if LVEF <= 57% (22%, consistent with #PARADIGMHF & #PIONEERHF ), is it time to see #Entresto HF outcomes studied in #HFmrEF ? #ESCcongress2019 #ACCPCardPRN
📌Making the Case for an Expanded Indication for #SacubitrilValsartan in #HeartFailure
🔸Greater benefit at lower #LVEF in #PARAGONHF
#CardioEd #CardioTwitter
Now out in Journal of Cardiac Failure, we describe the treatment effects of sac/val vs. val in patients with recent HF hosp in #PARAGONHF . Treatment benefits appear similar in those with lower (≤57%) vs. higher (>57%) EF. Potential implications for the ongoing #PARAGLIDEHF trial.
📌Probabilistic Readjudication of #HeartFailure Hospitalization Events in the #PARAGONHF Study
#CardioEd
Frustrating results from #PARAGONHF
Did the use of an active comparator (a ubiquitous but unproven rx in HFpEF) hamstring the experiment?
Stuart Connolly provides excellent commentary at #ESCCongress
Actualités dans l’insuffisance cardiaque au programme de ce soir avec les résultats de #PARAGONHF qui frôlent la significativité dans l’ICFEP et de #DAPAHF qui apportent un nouvel espoir dans l’ICFER
#ESC Congress #ESC congress2019 #WCC #cardiotwitter #ESC #Paris
#SimPub with European Society of Cardiology #HeartFailure2022 in Circulation
How does health status change before & after a HF 🏥?
Protocolized serial #KCCQ in #PARADIGMHF & #PARAGONHF uncovered worsening health status in months prior to HF🏥 with only partial recovery after
ahajournals.org/doi/10.1161/CI…
Continuous #heartFailure spetrum and #phenommaping as possible tools for depicting #sacubitril /valsartan response
Could Subphenotyping #HFpEF by #PulmonaryHypertension (with #diastolicdysfunction or #mitralregurgitation ) alter #PARAGONHF results?
#ESCCongress #WCC2019 #ESCCoT
New data from #PARAGONHF : Worsening #HeartFailure events (even when treated in ambulatory settings) are prognostically meaningful & should be considered in future RCTs in #HFpEF . bit.ly/3vCNslh
#JACCHF #CardioTwitter #MedTwitter #HFrEF
New paper by⭐️Brigham & Women's CV Fellows Maria A. Pabón, MD & Jon Cunningham in #EJHF on #HF RCT design
#PARAGONHF did not initially require all pts to have ↑ #NPs , but an early amendment standardized this requirement, leading to >60% ↑ events & the RCT to finish sooner.
onlinelibrary.wiley.com/doi/10.1002/ej…
#ACC24 #SimPub by Alberto Foà in JACC Journals
Fascinating observation from #PARAGONHF — pts w LVEF above 60% were at *higher* risk of hypotension & *lower* likelihood of benefit w #ARNI sacubitril/valsartan
Reinforces current guidance for pt selection
jacc.org/doi/10.1016/j.…